RE:RE:RE:RE:ONC fair value is $152.36 CDN or $114USDHere's what the Doctor said : "Considering that ONCY has the potential of increasing the effectiveness of PD-(L)1 inhibitors by 2-3x, Big Pharma companies that currently possess an immune checkpoint inhibitor appear significantly interested in acquiring ONCY (pelareorep) given pelareorep's ability to enhance checkpoint inhibitor efficacy while expanding the PD-(L)1 market in the process. Growing potential PD-(L)1 sales from US$67 Billion in 2027 to one that may be 2x or 3x greater would make any I/O like pelareorep a multi-billion product.
And any Big Pharma company seeking to differentiate their PD-(L)1 drugs from other PD-(L)1 inhibitors while gaining a bigger percentage of an expanded PD-(L)1 market, would certainly be interested in acquiring ONCY for the US$9-10 Billion that the above "fair value" per share figure represents."
"And the Doctor is seldom wrong!" .. according to the Doctor.